| Gina Fitzsimmons, DO | |
|
5649 Wynnewood Dr, Suite 203, Laurys Station, PA 18059-1138 | |
| (610) 261-1123 | |
| Not Available |
| Full Name | Gina Fitzsimmons |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 27 Years |
| Location | 5649 Wynnewood Dr, Laurys Station, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134152952 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD041833E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayada Home Health Care, Inc. | Bethlehem, PA | Home health agency |
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| Lehigh Valley Hospital | Allentown, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Luke's Physician Group Inc | 6709798333 | 1739 |
News Archive
Investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have conducted studies in mice to gain a new picture of how the immune system's "killer" T cells are prompted to destroy infected cells. Their insights provide a blueprint for rational design of vaccines that induce desired T-cell responses.
Tasigna (nilotinib) capsules have been approved with conditions in Canada as a new therapy for patients with CML, in the chronic phase (first phase) of the disease. Patients must be resistant to or intolerant of at least one prior therapy, including (Pr)Gleevec (imatinib mesylate), an established standard of care.
Researchers at the Spanish National Cancer Research Centre have discovered a genetic alteration that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia.
Microfluidic Systems, a privately-held company, announced today that they received patent number 7,607,641, entitled "Microfluidic Valve Mechanism". This patent covers a broad set of claims regarding the integration of a diaphragm membrane into a rigid body of a cartridge functioning as both a fluidic seal and cover of the cartridge, and as a valve mechanism for fluidics control within the cartridge.
A new variety of long-lasting insulin, called insulin degludec, lowers the risk of nighttime low blood sugar in elderly diabetic adults compared with insulin glargine, a systematic review of diabetes studies has found.
› Verified 6 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
Investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have conducted studies in mice to gain a new picture of how the immune system's "killer" T cells are prompted to destroy infected cells. Their insights provide a blueprint for rational design of vaccines that induce desired T-cell responses.
Tasigna (nilotinib) capsules have been approved with conditions in Canada as a new therapy for patients with CML, in the chronic phase (first phase) of the disease. Patients must be resistant to or intolerant of at least one prior therapy, including (Pr)Gleevec (imatinib mesylate), an established standard of care.
Researchers at the Spanish National Cancer Research Centre have discovered a genetic alteration that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia.
Microfluidic Systems, a privately-held company, announced today that they received patent number 7,607,641, entitled "Microfluidic Valve Mechanism". This patent covers a broad set of claims regarding the integration of a diaphragm membrane into a rigid body of a cartridge functioning as both a fluidic seal and cover of the cartridge, and as a valve mechanism for fluidics control within the cartridge.
A new variety of long-lasting insulin, called insulin degludec, lowers the risk of nighttime low blood sugar in elderly diabetic adults compared with insulin glargine, a systematic review of diabetes studies has found.
› Verified 6 days ago
| Entity Name | Lehigh Valley Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
Investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have conducted studies in mice to gain a new picture of how the immune system's "killer" T cells are prompted to destroy infected cells. Their insights provide a blueprint for rational design of vaccines that induce desired T-cell responses.
Tasigna (nilotinib) capsules have been approved with conditions in Canada as a new therapy for patients with CML, in the chronic phase (first phase) of the disease. Patients must be resistant to or intolerant of at least one prior therapy, including (Pr)Gleevec (imatinib mesylate), an established standard of care.
Researchers at the Spanish National Cancer Research Centre have discovered a genetic alteration that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia.
Microfluidic Systems, a privately-held company, announced today that they received patent number 7,607,641, entitled "Microfluidic Valve Mechanism". This patent covers a broad set of claims regarding the integration of a diaphragm membrane into a rigid body of a cartridge functioning as both a fluidic seal and cover of the cartridge, and as a valve mechanism for fluidics control within the cartridge.
A new variety of long-lasting insulin, called insulin degludec, lowers the risk of nighttime low blood sugar in elderly diabetic adults compared with insulin glargine, a systematic review of diabetes studies has found.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gina Fitzsimmons, DO Po Box 783311, Philadelphia, PA 19178-3311 Ph: () - | Gina Fitzsimmons, DO 5649 Wynnewood Dr, Suite 203, Laurys Station, PA 18059-1138 Ph: (610) 261-1123 |
News Archive
Investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have conducted studies in mice to gain a new picture of how the immune system's "killer" T cells are prompted to destroy infected cells. Their insights provide a blueprint for rational design of vaccines that induce desired T-cell responses.
Tasigna (nilotinib) capsules have been approved with conditions in Canada as a new therapy for patients with CML, in the chronic phase (first phase) of the disease. Patients must be resistant to or intolerant of at least one prior therapy, including (Pr)Gleevec (imatinib mesylate), an established standard of care.
Researchers at the Spanish National Cancer Research Centre have discovered a genetic alteration that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia.
Microfluidic Systems, a privately-held company, announced today that they received patent number 7,607,641, entitled "Microfluidic Valve Mechanism". This patent covers a broad set of claims regarding the integration of a diaphragm membrane into a rigid body of a cartridge functioning as both a fluidic seal and cover of the cartridge, and as a valve mechanism for fluidics control within the cartridge.
A new variety of long-lasting insulin, called insulin degludec, lowers the risk of nighttime low blood sugar in elderly diabetic adults compared with insulin glargine, a systematic review of diabetes studies has found.
› Verified 6 days ago
Courtney Elizabeth Pinkham, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5649 Wynnewood Dr Ste 203, Laurys Station, PA 18059 Phone: 610-261-1123 | |
Dr. Natalia Doni, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5649 Wynnewood Dr, Suite 203, Laurys Station, PA 18059 Phone: 610-261-1123 Fax: 610-262-1739 | |
Dr. Thomas Paul Harakal, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5649 Wynnewood Dr, Suite 202, Laurys Station, PA 18059 Phone: 610-261-1650 Fax: 610-261-9601 | |
Lisa Medina, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5649 Wynnewood Dr Ste 203, Laurys Station, PA 18059 Phone: 610-261-1123 Fax: 610-262-1739 | |
Daniel M Spatz, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5649 Wynnewood Dr, Suite 203, Laurys Station, PA 18059 Phone: 610-261-1123 | |
Lori Erschen, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5649 Wynnewood Dr, Suite 203, Laurys Station, PA 18059 Phone: 610-261-1123 |